Dopamine neurons coordinate smooth and controlled body movements, but new research indicates that when these cells are chronically overactivated, they degenerate and die. Scientists at Gladstone Institutes report that this process may explain a key feature of Parkinson’s disease, a condition that affects more than 8 million people worldwide and causes tremors, slowed movement, stiffness, and balance difficulties.

While researchers have long known that dopamine-producing neurons die in Parkinson’s disease, the cause of their heightened vulnerability has remained uncertain. The new study, published in eLife, shows in mice that chronic overactivation of these neurons can directly trigger their deterioration. Ken Nakamura, who led the study, summarized: “An overarching question in the Parkinson’s research field has been why the cells that are most vulnerable to the disease die. Answering that question could help us understand why the disease occurs and point toward new ways to treat it.”

To test their hypothesis, the scientists engineered dopamine neurons in mice to respond to the drug clozapine-N-oxide (CNO). By adding CNO to the mice’s drinking water, the researchers produced sustained activation of the neurons, modeling the prolonged overactivity believed to occur in Parkinson’s patients.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

“In previous work, we and others have transiently activated these cells with injections of CNO or by other means, but that only led to short bursts of activation,” says Katerina Rademacher, first author of the study. “By delivering CNO through drinking water, we get a relatively continuous activation of the cells, and we think that’s important in modeling what happens in people with Parkinson’s disease.”

The results emerged quickly. Within days, the animals’ normal daily activity cycles were disrupted. After a week, degeneration of dopamine neuron projections, known as axons, was evident. By one month, neurons had begun to die. This degeneration was largely confined to dopamine neurons in the substantia nigra, the brain region that governs movement—mirroring the selective cell loss seen in humans with Parkinson’s. Other dopamine neurons controlling motivation and emotion were largely spared.

Further experiments revealed molecular changes underlying this effect. Chronic overactivation disrupted calcium balance and altered expression of genes critical for dopamine metabolism. According to Rademacher, the neurons may attempt to limit dopamine production to avoid toxic excess, but over time this self-protective mechanism contributes to their death. Analyses of brain tissue from patients with early Parkinson’s showed similar gene expression shifts.

Although the study did not pinpoint why dopamine neurons become overactive in the first place, Nakamura suggested that genetic predispositions, environmental exposures, or compensatory responses to early neuron loss could be responsible. He concluded, “If that’s the case, it raises the exciting possibility that adjusting the activity patterns of vulnerable neurons with drugs or deep brain stimulation could help protect them and slow disease progression.”